Serotonergic psychedelic treatment for obesity and eating disorders: potential expectations and caveats for emerging studies
Journal of Psychiatry and Neuroscience June 1, 2022 Stephanie L. Borgland, Drew M. Neyens 14 citations
There has been a substantial growth in private clinics and registered clinical trials employing serotonergic psychedelics for various psychiatric illnesses, including substance use disorder[1][1],[2][2] and major depressive disorder.[3][3]–[6][4] Classical psychedelics include lysergic acid